8-Cl-Ado(8-Cl-Ado) - 药物靶点：RNA聚合酶_在研适应症：慢性淋巴细胞白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Adenosine, 8-chloro-、NSC-354258

靶点

RNA聚合酶

作用机制

RNA聚合酶抑制剂

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症

慢性淋巴细胞白血病

非在研适应症-

原研机构

National Cancer Institute

在研机构

北京大学医学部

National Cancer Institute

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C10H12ClN5O4

InChIKeyMHDPPLULTMGBSI-UUOKFMHZSA-N

CAS号34408-14-5

关联

100 项与 8-Cl-Ado 相关的临床结果

登录后查看更多信息

100 项与 8-Cl-Ado 相关的转化医学

登录后查看更多信息

100 项与 8-Cl-Ado 相关的专利（医药）

登录后查看更多信息

55

项与 8-Cl-Ado 相关的文献（医药）

2024-06-01·Leukemia

8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia

Article

作者: Liu, Wei ; Marcucci, Guido ; Wu, Xiwei ; Guo, Jiamin ; Chen, Zhenhua ; Patrick, Pirrotte ; Rosen, Steven T ; Li, Zhenlong ; Chen, Min-Hsuan ; Khyatiben, Pathak ; Moore, Roger E ; Ma, Rui ; Zhang, Yi ; Horne, David ; Nguyen, Le Xuan Truong ; Chen, Jianjun ; Du, Li ; Wang, Lili ; Yang, Yanzhong ; Che, Yuan ; Buettner, Ralf ; Su, Rui

Abstract:

Targeting the metabolic dependencies of acute myeloid leukemia (AML) cells is a promising therapeutical strategy. In particular, the cysteine and methionine metabolism pathway (C/M) is significantly altered in AML cells compared to healthy blood cells. Moreover, methionine has been identified as one of the dominant amino acid dependencies of AML cells. Through RNA-seq, we found that the two nucleoside analogs 8-chloro-adenosine (8CA) and 8-amino-adenosine (8AA) significantly suppress the C/M pathway in AML cells, and methionine-adenosyltransferase-2A (MAT2A) is one of most significantly downregulated genes. Additionally, mass spectrometry analysis revealed that Venetoclax (VEN), a BCL-2 inhibitor recently approved by the FDA for AML treatment, significantly decreases the intracellular level of methionine in AML cells. Based on these findings, we hypothesized that combining 8CA or 8AA with VEN can efficiently target the Methionine-MAT2A-S-adenosyl-methionine (SAM) axis in AML. Our results demonstrate that VEN and 8CA/8AA synergistically decrease the SAM biosynthesis and effectively target AML cells both in vivo and in vitro. These findings suggest the promising potential of combining 8CA/8AA and VEN for AML treatment by inhibiting Methionine-MAT2A-SAM axis and provide a strong rationale for our recently activated clinical trial.

2024-03-01·Cancer

A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics

Article

作者: Wang, Yan ; Rosen, Steven T ; Buettner, Ralf ; Gandhi, Varsha ; Tsai, Ni-Chun ; Synold, Timothy W ; Palmer, Joycelynne ; O'Hearn, James ; Marcucci, Guido ; Zhang, Jianying ; Pullarkat, Vinod ; Chen, Lisa S ; Truong Nguyen, Le Xuan

Abstract:

Background:

This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 8‐chloro‐adenosine (8‐Cl‐Ado) in patients with relapsed/refractory acute myeloid leukemia (AML).

Methods:

8‐Cl‐Ado was administered daily for 5 days; the starting dose was 100 mg/m2, the highest dose tested was 800 mg/m2. The end points were toxicity, disease response, and PK/PD measurements.

Results:

The predominant nonhematologic toxicity was cardiac with grade ≥3 toxicity. Plasma PK in all patients suggested heterogeneity among patients, yet, some dose‐dependency for the accumulation of 8‐Cl‐Ado. Two 8‐Cl‐Ado metabolites accumulated at similar levels to 8‐Cl‐Ado. Cellular PK in eight patients indicated accumulation of 8‐Cl‐ATP, which was associated with AML blast cytoreduction in peripheral blood. The authors determined the RP2D of 8‐Cl‐Ado to be 400 mg/m2.

Conclusions:

Given the cardiac adverse events observed, patients require monitoring for arrhythmias and QT interval during infusion. Although peripheral blood cytoreduction was observed, responses were transient, suggesting combination strategies will be required.

2023-12-01·Anticancer research

8-Chloroadenosine Induces ER Stress and Apoptotic Cell Death in Cholangiocarcinoma Cells

Article

作者: Svasti, Jisnuson ; Lertsuwan, Jomnarong ; Satayavivad, Jutamaad

BACKGROUND/AIM:

Cholangiocarcinoma is a lethal cancer, and current chemotherapeutic drugs are not very effective. Recent studies reported that cholangiocarcinoma cells were sensitive to adenosine. One adenosine analog, 8-chloroadenosine (8-CA), was shown to be more potent than adenosine and induced apoptosis in leukemia cells. This study examined effects of 8-CA in cholangiocarcinoma cells and immortalized cholangiocytes.

MATERIALS AND METHODS:

Cell growth was examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell invasion was examined by transwell assay. Cell cycle and cell death were evaluated by flow cytometry. Colorimetric absorbance assay was used to assessed RNA and protein synthesis as well as mitochondrial membrane potential. Protein levels were examined by western blot analysis. Animal experiment was performed in Balb/cAJcl-Nu mice.

RESULTS:

8-CA reduced cholangiocarcinoma cell growth, prevented colony formation and caused endoplasmic reticulum stress and cell-cycle arrest. Eventually, apoptosis was induced. However, treatment with 8-CA did not interfere with RNA synthesis or protein synthesis and did not alter mitochondrial membrane potential. Combination of 8-CA with several chemotherapeutic drugs in vitro was less effective than 8-CA alone and the drugs alone, except for the combination of 8-CA with hydroxychloroquine, which had an additive effect on RMCCA-1 cells. However, further in vivo study showed that treatment with 8-CA alone inhibited tumor growth more than treatment with a combination of 8-CA with hydroxychloroquine.

CONCLUSION:

8-Chloroadenosine inhibited CCA cells by inducing endoplasmic reticulum stress and apoptosis. In vivo study showed that 8-CA inhibited cholangiocarcinoma tumor growth better when administered alone as compared to a combination with hydroxychloroquine.

100 项与 8-Cl-Ado 相关的药物交易

登录后查看更多信息